Xenon Pharmaceuticals: New Insights on Azetukalner at AES 2024

Xenon Pharmaceuticals Presents Azetukalner Data at AES 2024

Xenon Pharmaceuticals Inc., a prominent neuroscience-focused biopharmaceutical company, has announced its participation at the upcoming American Epilepsy Society Annual Meeting (AES 2024). This event is scheduled to occur from December 6 to December 10, 2024, at the Los Angeles Convention Center. During this period, Xenon will present multiple scientific posters, showcasing vital findings related to azetukalner, a novel treatment for epilepsy.

Long-Term Data on Azetukalner

One of the key highlights of their presentation will be new long-term data from the ongoing X-TOLE open-label extension study. This research focuses on azetukalner’s effectiveness in treating patients suffering from focal onset seizures (FOS). The company has emphasized the need for reliable treatments for these patients, especially in recognizing and addressing the mental health burdens that often accompany epilepsy.

Posters Presented by Xenon

Xenon plans to present five posters at AES 2024, illustrating an extensive range of research findings:

Poster Presentation on Azetukalner

Poster 2.361 will detail the long-term safety and efficacy of azetukalner as a potent Kv7 potassium channel opener in adults with focal epilepsy. This session, led by Dr. Jacqueline A. French from New York University, is set for Sunday, December 8, from 12 PM to 2 PM PT.

Mental Health and Comorbidities

Another prominent presentation, Poster 2.347, will explore the mental health burden associated with focal onset seizures through a patient-reported outcomes study. This critical session aims to underscore the often-overlooked psychological challenges faced by patients. It will also take place on Sunday, December 8, from 12 PM to 2 PM PT.

Literature Review on Comorbidities

In addition, Poster 2.338 will provide a targeted literature review addressing the comorbidity challenges in FOS. This research is invaluable in understanding the complexities associated with epilepsy and its impact on patients.

Innovative Research on Nav1.1 Channels

Xenon will also showcase new findings in pre-clinical research with presentations dedicated to the Nav1.1 program. Posters will delve into how Nav1.1 potentiators influence brain rhythms in Dravet mouse models, with sessions scheduled for Monday, December 9. One of these posters (3.389) will focus on the modulation of brain rhythms measured through quantitative electrocorticography (qECoG), while another (3.395) will discuss how selective potentiation of Nav1.1 channels can restore interneuron function and improve motor abilities.

Hosting a Scientific Exhibit

In addition to presentations, Xenon will be hosting a Scientific Exhibit on December 8 from 2 PM to 5 PM PT. This exhibit will delve into their clinical and research programs, providing attendees an immersive experience into their groundbreaking efforts in epilepsy treatment.

Exhibit Hall Participation

Xenon will also have a presence in the Exhibit Hall with booths #1721 and #1827. The hall opens on December 7 at 12 PM PT and remains open until December 9 at 2 PM PT. This is an excellent opportunity for those interested in learning more about Xenon’s initiatives and advancements in epilepsy care.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc., traded on NASDAQ as XENE, is committed to the discovery and development of life-changing therapeutics for patients with neurological disorders. The company’s focus on ion channel product portfolios targets high unmet medical needs, particularly in conditions like epilepsy and depression.

Azetukalner stands out as a leading candidate in their offerings, being a highly potent and selective Kv7 potassium channel opener undergoing late-stage clinical development. Through extensive research and development, Xenon aims to provide enhanced therapeutic options for patients worldwide.

If you would like to learn more about Xenon Pharmaceuticals and their initiatives, visit their official website.

Frequently Asked Questions

What will Xenon Pharmaceuticals present at AES 2024?

Xenon will present multiple posters showcasing new long-term data on azetukalner and its effects on focal onset seizures, along with research on mental health and comorbidities.

When is AES 2024?

The American Epilepsy Society Annual Meeting (AES 2024) will take place from December 6-10, 2024.

Where can I find more information about their research?

Additional information about Xenon's research programs can be found on their official website.

What is Azetukalner?

Azetukalner is a novel Kv7 potassium channel opener aimed at treating focal onset seizures and is in late-stage clinical development.

How can I attend the Scientific Exhibit?

The Scientific Exhibit hosted by Xenon will take place on December 8, 2024, from 2 PM to 5 PM PT, providing an overview of their research programs.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.